February 1st, 2016
core view press release
OrthoEvidence™ presents CoreView™, a Curated, Objective, Relevant Evidence Viewpoint of critical topics in musculoskeletal research, highlighting and graphically summarizing evidence across our large database of ACE reports™ . CoreView™ specialty topics have a strong rationale with a deliberate focus on finding "signals" within an increasingly noisy environment of high-quality research in orthopaedics.
Why CoreView? Why now?
The presence of high-quality studies doesn't always translate to a clear message (more noise, less signal).
Clinical practice guidelines may lag behind new evidence and therefore become inconsistent with the best available evidence.
Position 3
Not all clinical trials are of the same quality. Randomized trials can also be biased and become a source of noise.
Our first product, the Advanced Clinical Evidence (ACE™) report, was designed to be a 700-word summary of an individual clinical trial to help busy practitioners identify important findings and quickly assess whether the study (randomized clinical trial, meta-analysis or systematic review) was worth examining in greater detail. We did this by including in each report a critical appraisal of the risk of bias and the methodology employed in the original publication.
With thousands of ACE™ reports in our database, we have the underlying data to create even more powerful reviews of broader topics that can inform areas of controversy or day-to-day practice. By bringing together evidence from multiple ACE™ reports we accomplish a rapidly updated, complete evidence picture of a specialty topic.
Osteoarthritis of the knee
  • Osteoarthritis is a massive healthcare burden that is clinically relevant to a variety of healthcare professionals.
  • Knee OA affects approximately 20-30% of adults and is expected to increase in incidence among the aging population.
  • It is the most common cause of lower limb disability, having an estimated $60 billion impact on the U.S. economy per year.
OA is well studied, with hundreds of high-quality publications on the topic. Despite the substantial body of research, recommendations are often inconsistent and methodologies can be difficult to follow. OE provides clarity by identifying treatment efficacy within specific patient populations (older, overweight or presenting with advanced disease severity) and intervention characteristics.
First osteoarthritis topic:
Intra-articular hyaluronic acid (IAHA)
  • Approved by the U.S. Food and Drug Administration for the treatment of knee OA in 1997.
  • A number of different IAHA products are commercially available, differing in properties such as molecular weight, dosing, and method of preparation.
  • There is an abundance of literature, with more than one hundred randomized-clinical trials and more than a dozen meta-analyses published on this particular topic.
Clearly, there is a considerable amount of high-quality evidence on the issue that can support recommendations and decisions. The challenge is that there is a lot of controversy in the literature regarding viscosupplementation of the knee with IAHA. We believe that it is important to distill the evidence in a way that can help clarify many of these issues and deliver the information required to effectively tailor therapy for patients with knee OA.
With CoreView™ , we provide a one-stop source to help guide decisions regarding the clinical applicability of the numerous treatment options for knee OA. CoreView™ is accessible via laptop, tablet, or smartphone. Using CoreView™, practitioners can more easily answer questions such as:
  • Does the efficacy of IAHA vary with molecular weight?
  • If I decide to give a patient IAHA injections, should I use a cross-linked or noncross-linked product?
  • Will IAHA therapy provide more favourable results in a selected patient population?
  • Will a certain subset of patients not benefit at all from this treatment?
CoreView™ OA charts and other content will be continuously updated as new evidence is published, and we will add additional CoreView™ topics every few months. As part of our product launch we have made CoreView™ OA free for all basic subscribers of OrthoEvidence™.
Visit us online at myorthoevidence.com
About OrthoEvidence™
OrthoEvidence™ was founded in 2009 by a global leader in the orthopaedic field, Dr. Mohit Bhandari. He is a recipient of the field's highest awards including the Royal College of Physicians and Surgeons Medal, the OREF/Kappa Delta Award and the Top Achievements of Health Care Research Award from Canadian Institutes of Health Research in association with the Canadian Medical Association Journal.
OrthoEvidence™'s repository includes thousands of ACE™ reports from more than 360 journals representing all sub-specialties, and new reports are added daily. Current research is typically summarized and posted within one month of being published, twice as fast as other evidence summary providers. Our reports are available to our growing membership of more than 15,000 practitioners, including surgeons, residents, nurses, physiotherapists and other allied healthcare professionals. Some of our partners include The Canadian Orthopaedic Association, ISAKOS (The International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports Medicine), Canadian Physiotherapy Association and the California Orthopaedic Association.